A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Targeted protein degradation is an attractive therapeutic strategy to deplete oncogenic proteins in tumours. Here the authors demonstrate the specific targeting of endogenous KRAS protein for degradation from cancer cells, and regression of tumours expressing mutant KRAS in a mouse model.
Guardado en:
Autores principales: | Nicolas Bery, Ami Miller, Terry Rabbitts |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/960ac50f46934b108f258aa4907c22dc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
por: Nicolas Bery, et al.
Publicado: (2019) -
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Jieqiong Wang, et al.
Publicado: (2016) -
Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
por: Tara Al Zubaidi, et al.
Publicado: (2021) -
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
por: Adham S. Bear, et al.
Publicado: (2021) -
Mutant KRAS promotes malignant pleural effusion formation
por: Theodora Agalioti, et al.
Publicado: (2017)